What additional therapy can be added for an asthmatic patient with increased phlegm and allergies who is already on daily Dulera (fluticasone/salmeterol) and an antihistamine?

Add a Leukotriene Receptor Antagonist (Montelukast)

For an asthmatic patient on Dulera with increased phlegm and allergies already taking an antihistamine, the most appropriate addition is a leukotriene receptor antagonist such as montelukast (Singulair) 10 mg once daily. This represents stepping up therapy according to NAEPP guidelines while specifically addressing both the allergic component and asthma control 1.

Clinical Reasoning

Since this patient is already on Dulera (mometasone/formoterol—a medium-dose ICS/LABA combination) with an antihistamine but continues to have symptoms, you need to step up therapy. According to the NAEPP stepwise approach, when a patient on Step 3-4 therapy (ICS/LABA combination) has inadequate control, the preferred next step is to add a leukotriene receptor antagonist as alternative adjunctive therapy 1.

Why Montelukast Specifically:

• Dual benefit: Montelukast addresses both asthma control AND allergic rhinitis symptoms, making it ideal for this patient with "increased allergies" 1
• Ease of use: Once-daily oral dosing improves compliance compared to additional inhaled medications 1
• Mucus reduction: Leukotriene antagonists help reduce airway inflammation and mucus production, directly addressing the "increased phlegm" complaint 1
• Synergistic effect: When combined with ICS/LABA therapy, montelukast provides additive anti-inflammatory benefits through a different mechanism of action 1

Alternative Considerations:

If montelukast is contraindicated (note the FDA boxed warning for neuropsychiatric effects) or ineffective after 4-6 weeks, consider:

1. Increase ICS dose: Move from medium-dose to high-dose ICS/LABA (Dulera 200 mcg/5 mcg) 1
2. Add intranasal corticosteroid: For the allergic rhinitis component specifically, adding fluticasone nasal spray provides superior nasal symptom control compared to montelukast alone 2, 3
3. Consider allergen immunotherapy: For Steps 2-4, subcutaneous immunotherapy should be considered for patients with documented allergic asthma 1, 4

Important Caveats:

First verify adherence and technique before adding medications. The guidelines explicitly state to "check adherence, environmental control, and comorbid conditions" before stepping up 1, 4. Many patients appear uncontrolled simply due to poor inhaler technique or non-adherence.

Monitor for increased rescue inhaler use: If the patient is using their short-acting beta-agonist more than 2 days per week for symptom relief (excluding pre-exercise use), this confirms inadequate control and justifies stepping up therapy 1.

Reassess in 2-6 weeks: After adding montelukast, evaluate response and consider further adjustments if symptoms persist 4.

What NOT to Do:

• Do not add another LABA: The patient is already on formoterol in Dulera; adding salmeterol or another LABA is contraindicated 1
• Avoid oral theophylline as first choice: While an alternative option, it requires serum monitoring and has more side effects than montelukast 1
• Don't jump to oral corticosteroids: Reserve systemic steroids for severe exacerbations or Step 6 therapy 1

The evidence strongly supports that adding montelukast to existing ICS/LABA therapy improves asthma outcomes, though the effect is more modest than initially adding the LABA to ICS 5, 6. For this patient with prominent allergic features, montelukast offers the best risk-benefit profile as the next therapeutic step.